Back
Insulet Corporation (PODD)
Health CarePODD · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$135.28
+0.60%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$3.44
ROE
23.0%
Gross margin
71.0%
Debt/Equity
0.78x
Revenue growth
33.9%
Insulet Corporation — company intelligence
Earnings surprises
Q2 2026$1.66 vs $1.48 est+12.2%
Q1 2026$1.42 vs $1.22 est+16.2%
Q4 2025$1.55 vs $1.48 est+4.5%
Q3 2025$1.24 vs $1.16 est+6.5%
Analyst consensus · 33 analysts
20 Buy13 Hold0 Sell
Updated Oct 9, 2026
Insider activity · 90 days
1 buy1 sellnet +856 shares
McEvoy AshleyBuy 1,100 · Aug 21, 2026
Davis Lisa BlairSell 244 · Aug 1, 2026
Recent SEC filings
8-K — Material event reportSep 21, 2026
8-K — Material event reportSep 16, 2026
8-K — Material event reportSep 10, 2026
Latest news
Insulet Reports Q2 2026 Results: Full Earnings Call Transcript — Benzinga · 2d ago
Intel downgraded, Marvell upgraded: Wall Street's top analyst calls — Yahoo · 3d ago
Barclays Initiates Coverage On Insulet with Equal-Weight Rating, Announces Price Target of $150 — Benzinga · 3d ago
Insulet (NASDAQ:PODD) Offers Affordable Growth With Strong Fundamentals — ChartMill · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.